Triaryl cation antibiotics from environmental DNA
Disclosed are triaryl cationic compounds that exhibit broad spectrum antibiotic and antifungal activity, pharmaceutical compositions containing the compounds, and methods of treating bacterial and fungal infections using the compounds. The compounds were initially isolated by screening a 25,000-member bacterial artificial chromosome (BAC) library of environmental (eDNA) from soil. At least one clone produced a dark brown melanin-like compound that was found to have antibiotic activity. The compounds were isolated and synthesized de novo. From within the positive clone, a single open reading frame that shares extensive sequence similarity with members of the 4-hydroxyphenylpyruvate family of enzymes was found to be necessary and sufficient to confer the production of at least one of the subject compounds on E. coli.
1. A method of treating bacterial or fungal infection in a subject in need thereof, the method comprising administering to the subject an antibiotic- or antifungal-effective amount of a compound selected from the group consisting of:
wherein each R is independently selected from the group consisting of hydrogen, halo, hydroxy, amino, unsubstituted C 1 to C 6 -alkyl, and C 1 to C 6 -alkyl substituted with one or more of halo, hydroxy, or amino; and R 1 is selected from the group consisting of hydrogen, halo, amino, unsubstituted C 1 to C 6 -alkyl, and C 1 to C 6 -alkyl substituted with one or more of halo, hydroxy, or amino; and pharmaceutically-acceptable salts thereof; in combination with a pharmaceutically-acceptable carrier.
2. The method of claim 1 , wherein a compound wherein each R is independently selected from the group consisting of hydrogen, halo, hydroxy, and unsubstituted C 1 to C 6 -alkyl is administered to the subject.
3. A method of treating bacterial or fungal infection in a subject in need thereof, the method comprising administering to the subject an antibiotic- or antifungal-effective amount of a compound of formula:
in combination with a pharmaceutically-acceptable carrier.
4. The method of claim 1 , wherein the compound is administered to a human subject.
5. The method of claim 1 , wherein the bacterial or fungal infection treated is selected from the group consisting of Erwinia herbicola, Escherichia coli, Salmonella typhimurium, Bacillus cereus, Bacillus subtilis, Staphylococcus aureus, Streptococcus pyogenes, Streptomyces griseus , and Candida guilliermondii.